Prot #VX20-121-103: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Resi

Project: Research project

Project Details

StatusActive
Effective start/end date1/25/22 → 1/25/26

Funding

  • Vertex Pharmaceuticals Incorporated ((OE) Prot #VX20-121-103)